These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 10499604

  • 1. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J, Boven E, Vermorken JB, Gall HE, van der Vijgh WJ.
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
    Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J.
    Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
    [Abstract] [Full Text] [Related]

  • 3. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D.
    Cancer Res; 1994 Feb 01; 54(3):709-17. PubMed ID: 8306332
    [Abstract] [Full Text] [Related]

  • 4. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N.
    Cancer Res; 1991 Mar 01; 51(5):1472-7. PubMed ID: 1997185
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D'Ambrosio S, Gibson-D'Ambrosio R, Chan KK.
    Cancer Chemother Pharmacol; 2002 May 01; 49(5):367-74. PubMed ID: 11976830
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
    Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, Alafaci E, Dutertre-Catella H, Bastian G.
    Cancer Chemother Pharmacol; 2000 May 01; 45(2):157-64. PubMed ID: 10663631
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
    Campone M, Rademaker-Lakhai JM, Bennouna J, Howell SB, Nowotnik DP, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Sep 01; 60(4):523-33. PubMed ID: 17308894
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA.
    Anticancer Res; 2003 Sep 01; 23(3C):2757-65. PubMed ID: 12926110
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
    Baur M, Drescher A, Gneist M, Dittrich C, Jaehde U.
    Cancer Chemother Pharmacol; 2008 Jan 01; 61(1):97-104. PubMed ID: 17396265
    [Abstract] [Full Text] [Related]

  • 10. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC.
    Clin Cancer Res; 2000 Oct 01; 6(10):3885-94. PubMed ID: 11051234
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
    O'Dwyer PJ, Hudes GR, Walczak J, Schilder R, LaCreta F, Rogers B, Cohen I, Kowal C, Whitfield L, Boyd RA.
    Cancer Res; 1992 Dec 15; 52(24):6746-53. PubMed ID: 1458462
    [Abstract] [Full Text] [Related]

  • 12. Clinical pharmacokinetics of oxaliplatin: a critical review.
    Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E.
    Clin Cancer Res; 2000 Apr 15; 6(4):1205-18. PubMed ID: 10778943
    [Abstract] [Full Text] [Related]

  • 13. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep 15; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 14. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis.
    Ishibashi T, Yano Y, Oguma T.
    Anticancer Res; 2005 Sep 15; 25(2B):1273-81. PubMed ID: 15865078
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.
    Lagrange JL, Médecin B, Etienne MC, Pivot X, Cassuto-Viguier E, Renée N, Thyss A, Ferrero JM, Otto J, François E, Milano G.
    Pharmacotherapy; 1997 Sep 15; 17(6):1246-53. PubMed ID: 9399607
    [Abstract] [Full Text] [Related]

  • 16. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP.
    Clin Cancer Res; 2004 May 15; 10(10):3386-95. PubMed ID: 15161693
    [Abstract] [Full Text] [Related]

  • 17. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
    Gietema JA, de Vries EG, Sleijfer DT, Willemse PH, Guchelaar HJ, Uges DR, Aulenbacher P, Voegeli R, Mulder NH.
    Br J Cancer; 1993 Feb 15; 67(2):396-401. PubMed ID: 8431374
    [Abstract] [Full Text] [Related]

  • 18. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
    Yamamoto N, Tamura T, Kurata T, Yamamoto N, Sekine I, Kunitoh H, Ohe Y, Saijo N.
    Cancer Chemother Pharmacol; 2009 Dec 15; 65(1):79-88. PubMed ID: 19396598
    [Abstract] [Full Text] [Related]

  • 19. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ.
    Cancer Res; 1994 Jan 01; 54(1):114-9. PubMed ID: 8261430
    [Abstract] [Full Text] [Related]

  • 20. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
    Gietema JA, Veldhuis GJ, Guchelaar HJ, Willemse PH, Uges DR, Cats A, Boonstra H, van der Graaf WT, Sleijfer DT, de Vries EG.
    Br J Cancer; 1995 Jun 01; 71(6):1302-7. PubMed ID: 7779728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.